ELVN-002 + Fam-Trastuzumab Deruxtecan-Nxki + Trastuzumab emtansine
Phase 1Active 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2 Mutant Non-small Cell Lung Cancer
Conditions
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Trial Timeline
Mar 20, 2023 → Jul 1, 2026
NCT ID
NCT05650879About ELVN-002 + Fam-Trastuzumab Deruxtecan-Nxki + Trastuzumab emtansine
ELVN-002 + Fam-Trastuzumab Deruxtecan-Nxki + Trastuzumab emtansine is a phase 1 stage product being developed by Enliven Therapeutics for HER2 Mutant Non-small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05650879. Target conditions include HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05650879 | Phase 1 | Active |
Competing Products
20 competing products in HER2 Mutant Non-small Cell Lung Cancer